Sigyn Therapeutics, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Sigyn Therapeutics, Inc. is a development-stage biotechnology company headquartered in San Diego, California, specializing in the development and commercialization of medical devices designed to treat cancer and infectious disease disorders. Its core product offerings include the Sigyn Therapy platform, a broad-spectrum blood purification technology that targets pathogen-associated inflammatory disorders such as endotoxemia, sepsis, community-acquired pneumonia, drug-resistant bacterial infections, and emerging pandemic threats. The company’s additional product candidates include ImmunePrep, which enhances the performance of immunotherapeutic antibodies; ChemoPrep, designed to improve the delivery of chemotherapy at tumor sites; and ChemoPure, aimed at reducing chemotherapy toxicity and preventing cancer metastasis. Sigyn also recently introduced the CardioDialysis device, which targets cardiovascular disease by reducing circulating inflammatory molecules and cholesterol. Founded in 2019, Sigyn Therapeutics focuses on creating therapeutic solutions that address unmet needs in global health, with applications particularly relevant to pharmaceutical, dialysis, and organ transplant industries. Its technologies leverage proprietary adsorbent components to remove bacterial toxins, inflammatory cytokines, viral pathogens, and other harmful substances from human blood plasma, with clinical validations conducted in vitro and in animal studies. The company’s Sigyn Therapy device is designed for integration with existing dialysis and continuous renal replacement therapy (CRT) machines commonly used in hospitals and clinics worldwide. In the last 1 to 2 years, Sigyn Therapeutics has made significant strategic advancements, including plans to submit multiple Breakthrough Device submissions to regulatory bodies and the initiation of a feasibility study for end-stage renal disease (ESRD) patients expected to generate data within months of completion. The company has also undergone corporate restructuring to progress toward Nasdaq listing requirements and has actively participated in investor and medical professional events to update on clinical milestones, regulatory developments, and technology validation results. These efforts underscore Sigyn’s commitment to advancing its therapeutic device pipeline and expanding its operational footprint in the United States and potentially global markets. These recent developments position Sigyn Therapeutics as a promising player advancing next-generation medical devices with potential applications in life-threatening inflammatory and infectious diseases, cancer care, and cardiovascular health management. The company maintains a lean operational structure with a focus on clinical and regulatory progress to support commercialization efforts within the healthcare technology sector.
Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
Head-To-Head Analysis: Sigyn Therapeutics (OTCMKTS:SIGY) vs. Shuttle Pharmaceuticals (NASDAQ:SHPH)
Sigyn Therapeutics, Inc. to Present at the LD Micro Main Event XIX
Sigyn Therapeutics, Inc. to Present at the LD Micro Main Event XIX
Sigyn Therapeutics to Present at the Life Sciences Virtual Investor Forum on September 18th
RETRANSMISSION: Goldman Small Cap Research Publishes New Research Report on Sigyn Therapeutics Inc.
Goldman Small Cap Research Publishes New Research Report on Sigyn Therapeutics Inc.
Sigyn Therapeutics to Present at Tomorrow's Small Cap Growth Virtual Investor Conference
Sigyn Therapeutics™ to Present at Tomorrow's Emerging Growth Conference
Sigyn Therapeutics™ Announces Filing of 2023 Annual Report on SEC Form 10-K
Sigyn Therapeutics Completes Reverse Stock Split
Sigyn Therapeutics Announces Reverse Stock Split
Sigyn Therapeutics Announces Appointment of Jerry DeCiccio as Chief Financial Officer
Sigyn Therapeutics Reports Third Quarter 2023 Financial Results
Sigyn Therapeutics™ Discloses PCT Patent Submission to Enhance Chemotherapy Delivery and Reduce Cancer Treatment Toxicity
Sigyn Therapeutics Reports Second Quarter 2023 Financial Results
Sigyn Therapeutics to Present at Tomorrow's Emerging Growth Conference
Sigyn Therapeutics to Present at the Bullseye Small Cap Virtual Investor Conference
Sigyn Therapeutics Featured on National Public Radio: “Addressing the Cytokine Storm”
Sigyn Therapeutics, Inc. Announces Participation in the Q3 Virtual Investor Summit